Lumos Diagnostics Holdings Limited operates as an integrated developer and manufacturer of point-of-care (POC) diagnostic tests.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.94|
|52 Week High||AU$0.82|
|52 Week Low||AU$1.50|
|1 Month Change||-13.36%|
|3 Month Change||-24.50%|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-28.24%|
Recent News & Updates
|LDX||AU Medical Equipment||AU Market|
Return vs Industry: Insufficient data to determine how LDX performed against the Australian Medical Equipment industry.
Return vs Market: Insufficient data to determine how LDX performed against the Australian Market.
Stable Share Price: LDX is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: Insufficient data to determine LDX's volatility change over the past year.
About the Company
Lumos Diagnostics Holdings Limited operates as an integrated developer and manufacturer of point-of-care (POC) diagnostic tests. The company develops and manufactures proprietary and in-licensed POC diagnostic tests. Its products include FebriDx, a test that differentiates between bacterial and viral respiratory infections; ViraDx, a combined COVID/Influenza test for acute respiratory infections; and CoviDx, an antigen test for COVID-19.
Lumos Diagnostics Holdings Fundamentals Summary
|LDX fundamental statistics|
Is LDX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|LDX income statement (TTM)|
|Cost of Revenue||AU$13.53m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.13|
|Net Profit Margin||-80.33%|
How did LDX perform over the long term?See historical performance and comparison
Is Lumos Diagnostics Holdings undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: LDX (A$0.94) is trading above our estimate of fair value (A$0.06)
Significantly Below Fair Value: LDX is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: LDX is unprofitable, so we can't compare its PE Ratio to the Australian Medical Equipment industry average.
PE vs Market: LDX is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate LDX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: LDX is good value based on its PB Ratio (1.8x) compared to the AU Medical Equipment industry average (4.5x).
How is Lumos Diagnostics Holdings forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LDX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: LDX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: LDX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: LDX's revenue (21.6% per year) is forecast to grow faster than the Australian market (5.5% per year).
High Growth Revenue: LDX's revenue (21.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: LDX is forecast to be unprofitable in 3 years.
How has Lumos Diagnostics Holdings performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: LDX is currently unprofitable.
Growing Profit Margin: LDX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if LDX's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare LDX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LDX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (74.9%).
Return on Equity
High ROE: LDX has a negative Return on Equity (-25.89%), as it is currently unprofitable.
How is Lumos Diagnostics Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: LDX's short term assets (A$76.1M) exceed its short term liabilities (A$43.2M).
Long Term Liabilities: LDX's short term assets (A$76.1M) exceed its long term liabilities (A$9.6M).
Debt to Equity History and Analysis
Debt Level: LDX is debt free.
Reducing Debt: LDX had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: LDX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: LDX has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 45.1% each year
What is Lumos Diagnostics Holdings's current dividend yield, its reliability and sustainability?
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate LDX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate LDX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if LDX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if LDX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of LDX's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dr. Robert P. Sambursky, M.D., also known as Rob, co-founded Rapid Pathogen Screening Inc. in 2004 and serves as its Executive Chairman, Chief Executive Officer, President and Chief Medical Officer. Dr. Sa...
CEO Compensation Analysis
Compensation vs Market: Rob's total compensation ($USD724.85K) is above average for companies of similar size in the Australian market ($USD302.72K).
Compensation vs Earnings: Insufficient data to compare Rob's compensation with company performance.
Experienced Management: LDX's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Experienced Board: LDX's board of directors are not considered experienced ( 0.9 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: LDX only recently listed within the past 12 months.
Lumos Diagnostics Holdings Limited's employee growth, exchange listings and data sources
- Name: Lumos Diagnostics Holdings Limited
- Ticker: LDX
- Exchange: ASX
- Founded: 2004
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: AU$141.143m
- Shares outstanding: 150.15m
- Website: https://lumosdiagnostics.com
- Lumos Diagnostics Holdings Limited
- Level 4
- 96-100 Albert Road
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/18 15:39|
|End of Day Share Price||2021/10/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.